Epigral Limited Schedules Video Conference Meeting with Dhamma Capital

1 min read     Updated on 09 Apr 2026, 05:27 PM
scanx
Reviewed by
Radhika SScanX News Team
AI Summary

Epigral Limited has scheduled a video conference meeting with Dhamma Capital for April 10, 2026, as part of its investor engagement activities. The meeting follows SEBI regulatory compliance requirements and ensures no unpublished price sensitive information will be shared, with relevant presentations already available on the company website.

powered bylight_fuzz_icon
36830089

*this image is generated using AI for illustrative purposes only.

Epigral Limited has announced a scheduled one-on-one meeting with Dhamma Capital through video conferencing, demonstrating the company's continued commitment to maintaining transparent communication with its investor community. The meeting represents a structured approach to investor relations under regulatory compliance.

Meeting Details

The one-on-one meeting has been organized with specific parameters to ensure effective institutional investor engagement:

Parameter: Details
Investor: Dhamma Capital
Date: April 10, 2026
Format: One-on-One Meeting
Mode: Video Conferencing
Location: N.A.

Regulatory Compliance

The announcement has been made pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This regulatory framework ensures that listed companies maintain appropriate disclosure standards when engaging with institutional investors. The company has emphasized that no unpublished price sensitive information will be shared or discussed during the meeting with investors.

Information Accessibility

Epigral Limited has confirmed that the latest earnings presentation and corporate presentation that may be discussed during the meeting have already been placed on the company's website at www.epigral.com . This proactive approach ensures that all relevant information is publicly accessible and maintains transparency in investor communications.

Schedule Flexibility

The company has noted that the schedule of the meeting is subject to change due to potential exigencies on the part of either the institutional investor or the company. This flexibility clause allows for necessary adjustments while maintaining the commitment to investor engagement. The formal communication was signed by Gaurang Trivedi, Company Secretary and Compliance Officer, on April 9, 2026.

Will Epigral Limited expand its investor outreach program to include more institutional investors following this structured engagement with Dhamma Capital?

How might Dhamma Capital's investment decision influence other institutional investors' interest in Epigral Limited's stock?

What strategic initiatives or business developments is Epigral likely to highlight in upcoming investor presentations to attract institutional funding?

Epigral Limited Files SEBI Compliance Certificate for Q4FY26

1 min read     Updated on 08 Apr 2026, 03:17 PM
scanx
Reviewed by
Radhika SScanX News Team
AI Summary

Epigral Limited submitted its SEBI Regulation 74(5) compliance certificate for Q4FY26 on 08.04.2026. The certificate, issued by registrar MUFG Intime India Private Limited, confirms proper processing of dematerialized securities during the quarter ended 31st March, 2026. All securities received from depository participants were confirmed within prescribed timelines, with security certificates properly mutilated and cancelled after verification, and depositories' names substituted in the register of members as registered owners.

powered bylight_fuzz_icon
37187243

*this image is generated using AI for illustrative purposes only.

Epigral Limited has filed its quarterly compliance certificate under SEBI Regulation 74(5) for the quarter ended 31st March, 2026. The regulatory filing was submitted to both the National Stock Exchange of India Limited and BSE Limited on 08.04.2026, signed by Company Secretary and Compliance Officer Gaurang Trivedi.

Regulatory Compliance Certificate Details

The certificate was issued by MUFG Intime India Private Limited (formerly Link Intime India Private Limited), which serves as the company's Registrar and Share Transfer Agent. The compliance document confirms adherence to Securities and Exchange Board of India (Depositories and Participants) Regulation, 2018.

Parameter: Details
Reporting Period: Quarter ended 31st March, 2026
Filing Date: 08.04.2026
Registrar: MUFG Intime India Private Limited
Certificate Date: 01-04-2026
Signatory: Gaurang Trivedi, Company Secretary

Certificate Confirmation Details

MUFG Intime India Private Limited confirmed that all securities received from depository participants for dematerialization during Q4FY26 were properly processed. The registrar verified that:

  • Securities received for dematerialization were confirmed or rejected to depositories within prescribed timelines
  • Security certificates comprised in the dematerialization requests have been listed on stock exchanges where earlier issued securities are listed
  • Security certificates received were mutilated and cancelled after due verification by depository participants
  • Names of depositories were substituted in the register of members as registered owners within prescribed timelines

Registrar Information

MUFG Intime India Private Limited, with CIN U67190MH1999PTC118368, operates from its registered address at C-101, Embassy 247, L.B.S. Marg, Vikhroli (West), Mumbai - 400083. The certificate was signed by Ashok Shetty, Sr. Vice President-Corporate Registry, confirming the company's compliance with regulatory requirements for the quarter.

This quarterly filing represents part of Epigral Limited's ongoing regulatory compliance obligations under SEBI regulations governing depositories and participants.

What impact might MUFG Intime India's rebranding from Link Intime have on Epigral's future registrar and transfer agent services?

How could Epigral's consistent regulatory compliance position affect its stock performance and investor confidence in upcoming quarters?

What strategic initiatives might Epigral announce in their upcoming annual results following this Q4FY26 compliance filing?

More News on Epigral